Last reviewed · How we verify
Orient Pharma Co., Ltd. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
4 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Placebo First, then ORADUR® | Placebo First, then ORADUR® | phase 3 | Opioid partial agonist | Opioid receptors | Pain management | |
| 1PC111 | 1PC111 | phase 3 | PI3K inhibitor | PI3K | Oncology | |
| 1PC002 | 1PC002 | phase 3 | PI3K inhibitor | PI3K | Oncology | |
| ORADUR®-Methylphenidate | ORADUR®-Methylphenidate | phase 3 | Sympathomimetic amine; central nervous system stimulant | Dopamine transporter (DAT); Norepinephrine transporter (NET) | Neurology / Psychiatry |
Therapeutic area mix
- Oncology · 2
- Neurology / Psychiatry · 1
- Pain management · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Addpharma Inc. · 1 shared drug class
- Aevi Genomic Medicine, LLC, a Cerecor company · 1 shared drug class
- Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
- Amorphical Ltd. · 1 shared drug class
- Angitia Incorporated Limited · 1 shared drug class
- Applied Biology, Inc. · 1 shared drug class
- Aptarion Biotech AG · 1 shared drug class
- AB Science · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Orient Pharma Co., Ltd.:
- Orient Pharma Co., Ltd. pipeline updates — RSS
- Orient Pharma Co., Ltd. pipeline updates — Atom
- Orient Pharma Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Orient Pharma Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/orient-pharma-co-ltd. Accessed 2026-05-15.